Prevention of β-cell destruction in autoimmune diabetes: Current approaches and future prospects

Advances in Experimental Medicine and Biology

Volumn 654, Issue , 2010, Pages 611-626

  Sedimbi, Saikiran K ^a   Sanjeevi, Carani B ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

cell; Antibody based therapy; Antigen based therapy; Type 1 Diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; BCG VACCINE; CYCLOSPORIN; DNA VACCINE; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCOSE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN CHOLERA TOXIN B SUBUNIT CONJUGATE; INTERLEUKIN 10; INTERLEUKIN 4; MICROSPHERE; MONOCLONAL ANTIBODY CD3; NICOTINAMIDE; PEPTIDE; PEPTIDE DIAPEP277; PLACEBO; RITUXIMAB; SITAGLIPTIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN; VITAMIN D; ANTIBODY; ANTIGEN; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; CELL DESTRUCTION; CELL PROTECTION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE COURSE; DOWN REGULATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG OVERDOSE; DRUG POTENTIATION; GENE GUN IMMUNIZATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPHOCYTE DEPLETION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; CYTOLOGY; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY;

ANIMALIA;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; MODELS, BIOLOGICAL; VACCINES, DNA;

EID: 77953953258     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-90-481-3271-3_26     Document Type: Review

References (70)

1. Cosimi AB, Burton, RC, Colvin, RB, Goldstein G, Delmonico FL, Laquaglia, MP, Tolkoffrubin N, Rubin, RH, Herrin, JT, Russell PS. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981a;32:535.
2. Chatenoud LE, Thervet JJ, Primo JF Bach. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91:123-7.
3. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158: 2947-54. (Pubitemid 127470558)
4. Wong JT, Colvin RB. Selective reduction and proliferation of the CD4ρ and CD8ρ T cell subsets with bispecific monoclonal antibodies: Evidence for inter-T cell-mediated cytolysis. Clin Immunol Immunopathol 1991;58:236.
5. Hirsch R, Eckhaus M, Auchincloss HJR, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988;1040:3766.
6. Carpenter PA, Pavlovic S, Tso JY, Press OW, Gooley T, Yu XZ, Anasetti C. Non-Fc receptorbinding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol 2000;165:6205.
7. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9:1202.
8. Li MO, Wan YY, Sanjabi S, Robertson AK, and Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99.
9. Rutella S, Danese S, and Leone G. Tolerogenic dendritic cells: Cytokine modulation comes of age. Blood 2006;108:1435.
10. You S, Candon S, Kuhn C, Bach JF, Chatenoud L. CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes. Adv Immunol 2008;100:13-37.
11. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L. et al. Insulin needs after CD3- antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598.
12. Herold KC, Hagopian W, Auger JA, Poumian Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 2002;346:1692.
13. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, and Herold KC. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007;148:5136.
14. Routledge EG, Falconer ME, Pope H, Lloyd IS, aldmann H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 1995;60:847-53.
15. Bolt S. et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993;23:403-11. (Pubitemid 23075070)
16. Green EA, Flavell RA. Tumor necrosis factor-alpha and the progression of diabetes in nonobese diabetic mice. Immunol Rev 1999;169:11-22. (Pubitemid 29338719)
17. Wong FS, Wen L. B cells in autoimmune diabetes. Rev Diabet Stud 2005;2:121-35.
18. Brodie GM, Wallberg M, Santamaria P, Wong FS, Green EA B-cells promote intra-islet CD8+ cytotoxic T-cell survival to enhance type 1 diabetes. Diabetes 2008 Apr;57(4):909-17.
19. Rastetter W, Molina A, and White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503. (Pubitemid 38316738)
20. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006;24:467-96.
21. Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, Shlomchik MJ, Wen L. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007 Dec;117(12): 3857-67. (Pubitemid 350224095)
22. Xiu Y, Wong CP, Bouaziz JD, Hamaguchi Y, Wang Y, Pop SM, Tisch RM, Tedder TF. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol 2008 Mar 1;180(5):2863-75.
23. Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L; Type 1 Diabetes TrialNet Study Group. Type 1 Diabetes TrialNet - an international collaborative clinical trials network. Ann N Y Acad Sci 2008 Dec;1150:14-24.
24. Elias D, Cohen IR, Markovits D. et al. Peptide therapy for diabetes in NOD mice. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Lancet 1994;343:704-6.
25. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, doubleblind, phase II trial. Lancet 2001;358:1749-53. (Pubitemid 33152998)
26. Elias D, Avron A, Tamir M, Raz I. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann N Y Acad Sci 2006 Oct;1079:340-4. (Pubitemid 44968744)
27. Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D, Phillip M, Josefsberg Z. Heatshock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007 May;23(4):286-91. (Pubitemid 46851469)
28. Kaufman D, Clare-Salzar M. et al. Spontaneous loss of T cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993;366:69-72. (Pubitemid 23345238)
29. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmér M, Harris RA, Robertson JA. Lernmark A Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005 Jul-Aug;19(4):238-46. (Pubitemid 40910206)
30. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes N Engl J Med 2008 Oct 30;359(18):1909-20.
31. Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, Lindblad M, Mayer A, Czerkinsky C, Holmgren J, Thivolet C. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A 1997;94(9):4610-4. (Pubitemid 27194290)
32. Gong Z, Jin Y, Zhang Y. Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in silkworm. Vaccine 2007 Feb 9;25(8):1444-51. (Pubitemid 46074297)
33. Diabetes Prevention Trial-Type 1 Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
34. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of oral insulin in relatives of patients with type 1 diabetes mellitus. Diabetes Care 2005;28:1068-76.
35. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008 Nov 15;372(9651):1746-55.
36. Achenbach P, Barker J, Bonifacio E. Pre-POINT Study Group. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008 Apr;8(2):87-93.
37. Waeckerle-Men Y, Allmen EU, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HP, Groettrup M. Encapsulation of proteins and peptides into biodegradable poly(D, L-lactide-coglycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 2006;24:1847-57. (Pubitemid 43238266)
38. Yoshida M, Babensee JE. Molecular aspects of microparticle phagocytosis by dendritic cells. J Biomater Sci Polym Ed 2006;17:893-907.
39. Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, Gillis K, Brown L, Lafreniere D, Gallo M, Knox J, Hogeland K, Trucco M, Giannoukakis N. A microspherebased vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 2008 Jun;57(6):1544-55.
40. Tarbell KV, Yamazaki S, Steinman RM. The interactions of dendritic cells with antigenspecific, regulatory T cells that suppress autoimmunity. Semin Immunol 2006;18:93-102. (Pubitemid 43248737)
41. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL. et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine N Engl J Med 1988 Mar 17;318(11):663-70. (Pubitemid 18083606)
42. Behme MT, Dupre J, Stiller CR. Effect of cyclosporine on insulin binding to erythrocytes in type 1 diabetes mellitus of recent onset. Clin Invest Med 1988 Apr;11(2):113-22.
43. Yamada K. et al. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with nsulitis. An observation in nonobese diabetic (NOD) mice. Diabetes 1982;31:749-53. (Pubitemid 12062862)
44. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes Lancet 2004 Mar 20;363(9413):925-31.
45. Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes: a randomized clinical study. Diabetes Care 1999;22:1703-7. (Pubitemid 29458397)
46. Huppmann M, Baumgarten A, Ziegler AG, Bonifacio E. Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care 2005 May;28(5):1204-6. (Pubitemid 40616636)
47. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann N Y Acad Sci 2008 Dec;1150:1-13.
48. Prud'homme GJ. Prevention of autoimmune diabetes by DNA vaccination. Expert Rev Vaccines 2003 Aug;2(4):533-40.
49. Tisch R, Wang B, Weaver DJ. et al. Antigen-specific mediated suppression of β-cell autoimmunity by plasmid DNA vaccination. J Immunol 2001;166:2122-32. (Pubitemid 32114703)
50. Kevin S Goudy, Bo Wang, Roland Tisch. Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice Clinical immunology 2008;129:49-57.
51. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1, 25 dihydroxyvitamin D3. Diabetologia 1994;37:552-8. (Pubitemid 24162425)
52. TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) Pediatr Diabetes 2007 Jun;8(3):117-37.
53. Luopajärvi K, Savilahti E, Virtanen SM, Ilonen J, Knip M, Akerblom HK, Vaarala O. Enhanced levels of cow's milk antibodies in infancy in children who develop type 1 diabetes later in childhood. Pediatr Diabetes 2008 Oct;9(5):434-41.
54. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002 May;109(10):1321-6. (Pubitemid 34546896)
55. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002 Feb;87(2):563-8. (Pubitemid 34158219)
56. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003 Jan;166(1):129-35. (Pubitemid 35449608)
57. Sanjeevi CB, Lybrand TP, Landin-Olsson M. et al. Analysis of antibody markers, DRB1, DRB5, DQA1 and DQB1 genes and modeling of DR2 molecules in DR2 positive patients with type 1 diabetes. Tissue Antigens 1994;44:110-9. (Pubitemid 24262463)
58. Sanjeevi CB, Lybrand TP, Deweese C. et al. Polymorphic amino acids variations in HLA-DQ are associated with systematic physical property changes and occurrence of insulin-dependent diabetes mellitus. Diabetes 1995;44:125-31.
59. Sanjeevi CB, Landin-Olsson M, Kockum I. et al. Effects of the second haplotype on the association with childhood insulin-dependent diabetes mellitus. Tissue Antigens 1995;45:148-52.
60. Sanjeevi CB, Höök P, Landin-Olsson M. et al. Analysis of DR4 subtypes and their molecular properties in a population based study of Swedish childhood diabetes. Tissue Antigens 1996;47:275-83. (Pubitemid 26148175)
61. Graham J, Kockum I, Sanjeevi CB, et al. Negative association between type 1 diabetes and HLA DQB1-0602-DQA1-0102 is attenuated with age at onset. Swedish Childhood Diabetes Study Group. Eur J Immunogenet 1999;26:117-28.
62. Roll U, Christie MR, FüchtenbuschM, PaytonMA, Hawkes CJ, Ziegler AG. Perinatal autoimmunity in offspring of diabetic parents: the German multicenter BABY-DIAB study. Diabetes 1996;45:967.
63. Ludvigsson J, Gustafsson-Stolt U, Liss PE, Svensson T. ABIS Study Group. Mothers of children in ABIS, a population-based screening for prediabetes, experience few ethical conflicts and have a positive attitude. Ann N Y Acad Sci 2002 Apr;958:376-81. (Pubitemid 34592265)
64. Hadjiyanni I, Baggio, LL. et al. Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 2008;149(3): 1338-49. (Pubitemid 351397945)
65. Hadjiyanni I, Drucker DJ. Glucagon-like peptide 1 and type 1 diabetes: NOD ready for prime time? Endocrinology 2007;148(11):5133-5. (Pubitemid 350012613)
66. Song Xue, clive Wasserfall, Mathew Parker, Sean Mcgrail, Kieran McGail, Martha Campbell- Thompson, Desmond A Schatx, Mark A Atkinson, Micheal J Haller. Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area. J Diab Compli 2009.
67. Mu J, Woods J, Zhou Y-P, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-704. (Pubitemid 44324122)
68. Duttaroy A, Voelker F, Merriam LQ, Zhang X, Ren X, Burkey B. The DPP-4 inhibitor Vildagliptin increases pancreatic β-cell neogenesis and decreases apoptosis. Diabetes 2005;54(Suppl 1):A141 [Abstract 572-P].
69. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-94. (Pubitemid 41159387)
70. Bernardo L. Wajchenberg. β-Cell Failure in Diabetes and Preservation by Clinical Treatment. Endocrine Reviews 2007;28(2):187-218. (Pubitemid 46984834)